A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

Prostate cancer screening compares favorably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research. The findings are ...

Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding ...

Among prostate cancer patients under active surveillance, low testosterone levels were associated with a statistically significant increased risk of "extreme" progression to grade group 3 or higher ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer.

Having a prostate-specific antigen (PSA) test result above 4.0 ng/mL is considered abnormal and it is worth closer testing, a physician said yesterday, as he suggested individuals with a family ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Graham Heron from Dorset urges UK men to get PSA tests for early prostate cancer detection, credits Dorchester Hospital and ...